佛慈制药以2000万元增资科近泰基 切入放射性同位素药物领域

Core Viewpoint - Lanzhou Foci Pharmaceutical Co., Ltd. has signed an investment agreement with KJT Technology Co., Ltd., marking its entry into the promising field of radioactive isotope drugs [2][3] Group 1: Investment Details - The company invested 20 million yuan in KJT Technology, acquiring a 4.91% stake [2] - KJT Technology is a wholly-owned subsidiary of the Institute of Modern Physics, Chinese Academy of Sciences, focusing on ion accelerator solutions and advanced research equipment [2] Group 2: Strategic Implications - This investment positions the company strategically in the upstream of the nuclear medicine industry, securing core resources for future development in radioactive drug research and production [3] - The collaboration with KJT Technology aligns with national and provincial policies promoting high-end pharmaceutical industries, enhancing the company's competitiveness and technological capabilities [3]